Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1002670_Vilaprisan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | Treatment A (Period 1): a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam Treatment B (Period 2): 600 mg Rifampicin once daily (qd) for 7 days followed by administration of a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam followed by 600 mg Rifampicin 12 hours after Vilaprisan and Midazolam administration and continued dosing of 600 mg Rifampicin once daily for 3 days |
| Name | Type | Description |
|---|---|---|
| Rifampicin | DRUG | 11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin. |
| Midazolam | DRUG | 2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam |
| BAY1002670_Vilaprisan | DRUG | 2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan |
Inclusion Criteria: * Healthy female postmenopausal subjects * Age: 45 to 65 years (inclusive) * Body mass index (BMI) : ≥20 and ≤32 kg/m² * Race: White Exclusion Criteria: * Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinica...
BAY1002670_Vilaprisan is an investigational small molecule developed by Bayer AG for endometriosis, an endocrine condition. It is in Phase 1 clinical development and has been studied in a completed drug-drug interaction trial. It is not described as approved.
BAY1002670_Vilaprisan is being developed for endometriosis, a condition in which tissue similar to the uterine lining grows outside the uterus. The clinical program has focused on this indication, with a completed Phase 1 drug-drug interaction study conducted in Germany.
BAY1002670_Vilaprisan is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor of the clinical program for this investigational small molecule in endometriosis.
BAY1002670_Vilaprisan is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. It is an investigational agent and is not described as approved for any indication.
BAY1002670_Vilaprisan has been studied in one completed Phase 1 trial, NCT02975440, titled a drug-drug interaction study between orally administered rifampicin and vilaprisan. The trial enrolled 12 participants in Germany, was uncontrolled, and included healthy female volunteers aged 45 years and older.
Yes, BAY1002670_Vilaprisan is also known as vilaprisan. The two names refer to the same investigational small molecule developed by Bayer AG for endometriosis, and the completed Phase 1 trial NCT02975440 uses the vilaprisan name.